Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

γTools: A modular multifunction phantom for quality assurance in GammaKnife treatments.

Calusi S, Noferini L, Marrazzo L, Casati M, Arilli C, Compagnucci A, Talamonti C, Scoccianti S, Greto D, Bordi L, Livi L, Pallotta S.

Phys Med. 2017 Nov;43:34-42. doi: 10.1016/j.ejmp.2017.10.010. Epub 2017 Oct 21.

PMID:
29195560
2.

Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy.

Melvin AJ, Warshaw M, Compagnucci A, Saidi Y, Harrison L, Turkova A, Tudor-Williams G; PENPACT-1 (PENTA 9/PACTG 390/ANRS 103) Study Team.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e109-e115. doi: 10.1093/jpids/pix050.

PMID:
28903520
3.

Paediatric European Network for Treatment of AIDS Treatment Guideline 2016 update: antiretroviral therapy recommended for all children living with HIV.

Foster C, Bamford A, Turkova A, Welch S, Klein N; PENTA Guidelines Writing Group and PENTA steering committee.

HIV Med. 2017 Feb;18(2):133-134. doi: 10.1111/hiv.12399. Epub 2016 Jul 6. No abstract available.

4.

The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children.

Palma P, Foster C, Rojo P, Zangari P, Yates A, Cotugno N, Klein N, Luzuriaga K, Pahwa S, Nastouli E, Gibb DM, Borkowsky W, Bernardi S, Calvez V, Manno E, Mora N, Compagnucci A, Wahren B, Muñoz-Fernández M, De Rossi A, Ananworanich J, Pillay D, Giaquinto C, Rossi P.

J Virus Erad. 2015;1(3):134-139. Epub 2015 Jun 30.

5.

Gamma Knife Radiosurgery in the management of single and multiple brain metastases.

Greto D, Scoccianti S, Compagnucci A, Arilli C, Casati M, Francolini G, Cecchini S, Loi M, Desideri I, Bordi L, Bono P, Bonomo P, Meattini I, Detti B, Livi L.

Clin Neurol Neurosurg. 2016 Feb;141:43-7. doi: 10.1016/j.clineuro.2015.12.009. Epub 2015 Dec 18.

PMID:
26731463
6.

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption.

Ananworanich J, Melvin D, Amador JT, Childs T, Medin G, Boscolo V, Compagnucci A, Kanjanavanit S, Montero S, Gibb DM; PENTA 11 Study Group.

AIDS. 2016 Apr 24;30(7):1075-81. doi: 10.1097/QAD.0000000000001011.

PMID:
26730569
7.

GafChromic(®) EBT3 films for patient specific IMRT QA using a multichannel approach.

Marrazzo L, Zani M, Pallotta S, Arilli C, Casati M, Compagnucci A, Talamonti C, Bucciolini M.

Phys Med. 2015 Dec;31(8):1035-1042. doi: 10.1016/j.ejmp.2015.08.010. Epub 2015 Oct 1.

PMID:
26429383
8.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

9.

HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.

Harrison L, Melvin A, Fiscus S, Saidi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, McKinney R, Gibb D, Tudor-Williams G; PENPACT-1 (PENTA 9PACTG 390) Study Team.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):42-53. doi: 10.1097/QAI.0000000000000671.

10.

A nested case-control study on dietary fat consumption and the risk for gallstone disease.

Compagnucci AB, Perroud HA, Batallés SM, Villavicencio R, Brasca A, Berli D, Pezzotto SM.

J Hum Nutr Diet. 2016 Jun;29(3):338-44. doi: 10.1111/jhn.12332. Epub 2015 Aug 7.

PMID:
26249795
11.

Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission.

Klein N, Palma P, Luzuriaga K, Pahwa S, Nastouli E, Gibb DM, Rojo P, Borkowsky W, Bernardi S, Zangari P, Calvez V, Compagnucci A, Wahren B, Foster C, Munoz-Fernández MÁ, De Rossi A, Ananworanich J, Pillay D, Giaquinto C, Rossi P.

Lancet Infect Dis. 2015 Sep;15(9):1108-1114. doi: 10.1016/S1473-3099(15)00052-3. Epub 2015 Jul 14.

PMID:
26187030
12.

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.

Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, Gousset M, Avettand-Fenoël V, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML; French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups; French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups.

J Antimicrob Chemother. 2015 Jul;70(7):2084-9. doi: 10.1093/jac/dkv049. Epub 2015 Feb 26.

PMID:
25885327
13.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

14.

Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.

Deuzing IP, Charpentier C, Wright DW, Matheron S, Paton J, Frentz D, van de Vijver DA, Coveney PV, Descamps D; ANRS CO5 HIV-2 Cohort, Boucher CA, Beerens N.

J Virol. 2015 Jan;89(1):833-43. doi: 10.1128/JVI.02259-14. Epub 2014 Oct 29.

15.

Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.

Yin DE, Warshaw MG, Miller WC, Castro H, Fiscus SA, Harper LM, Harrison LJ, Klein NJ, Lewis J, Melvin AJ, Tudor-Williams G, McKinney RE Jr; PENPACT-1 (PENTA 9/PACTG 390) Study Team.

Pediatrics. 2014 Oct;134(4):e1104-16. doi: 10.1542/peds.2014-0527.

16.

Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.

Bastiaans DE, Forcat S, Lyall H, Cressey TR, Hansudewechakul R, Kanjanavanit S, Noguera-Julian A, Königs C, Inshaw JR, Chalermpantmetagul S, Saïdi Y, Compagnucci A, Harper LM, Giaquinto C, Colbers AP, Burger DM; PENTA 18KONCERT Study Group.

Pediatr Infect Dis J. 2014 Mar;33(3):301-5. doi: 10.1097/INF.0000000000000014.

PMID:
24356253
17.

The immunological and virological consequences of planned treatment interruptions in children with HIV infection.

Klein N, Sefe D, Mosconi I, Zanchetta M, Castro H, Jacobsen M, Jones H, Bernardi S, Pillay D, Giaquinto C, Walker AS, Gibb DM, De Rossi A; Paediatric European Network for Treatment of AIDS 11 Trial Team.

PLoS One. 2013 Oct 23;8(10):e76582. doi: 10.1371/journal.pone.0076582. eCollection 2013.

18.

Sexually-transmitted/founder HIV-1 cannot be directly predicted from plasma or PBMC-derived viral quasispecies in the transmitting partner.

Frange P, Meyer L, Jung M, Goujard C, Zucman D, Abel S, Hochedez P, Gousset M, Gascuel O, Rouzioux C, Chaix ML; ANRS PRIMO Cohort Study Group.

PLoS One. 2013 Jul 9;8(7):e69144. doi: 10.1371/journal.pone.0069144. Print 2013.

19.

Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.

Tubiana R, Mandelbrot L, Le Chenadec J, Delmas S, Rouzioux C, Hirt D, Treluyer JM, Ekoukou D, Bui E, Chaix ML, Blanche S, Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group.

Clin Infect Dis. 2013 Sep;57(6):891-902. doi: 10.1093/cid/cit390. Epub 2013 Jun 12.

PMID:
23766338
20.

Preexposure prophylaxis (PrEP) of HIV infection in France: a nationwide cross-sectional study (PREVIC study).

Rosenthal E, Piroth L, Cua E, Joulié A, Ravaux I, Chauveau M, Lacombe K, Cotte L, Bonnard P, Weiss L, Longuet M, Pradier C, Cacoub P; GERMIVIC Study Group.

AIDS Care. 2014 Feb;26(2):176-85. doi: 10.1080/09540121.2013.803014. Epub 2013 Jun 11.

PMID:
23756091

Supplemental Content

Loading ...
Support Center